UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1005-14
Program Prior Authorization/Notification
Medication Ampyra® (dalfampridine)
P&T Approval Date 5/2010, 5/2011, 5/2012, 5/2013, 5/2014, 5/2015, 5/2016, 5/2017,
5/2018, 5/2019, 5/2020, 5/2021, 5/2022, 5/2023, 5/2024, 5/2025
Effective Date 8/1/2025
1. Background:
Ampyra® (dalfampridine) is a potassium channel blocker indicated to improve walking in
patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.1
2. Coverage Criteriaa:
A. Initial Authorization
1. Ampyra will be approved based on both of the following criteria:
a. Diagnosis of multiple sclerosis
-AND-
b. Physician confirmation that patient has difficulty walking (e.g., Timed 25-foot Walk)
Authorization will be issued for 12 months.
B. Reauthorization
1. Ampyra will be approved based on the following criteria:
a. Physician confirmation that the patient’s walking improved with Ampyra therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2025 UnitedHealthcare Services, Inc.
1
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Ampyra [package insert]. Acorda Therapeutics, Inc. Ardsley, NY. June 2022.
Program Prior Authorization/Notification – Ampyra (dalfampridine)
Change Control
5/2014 Annual review with no change to criteria.
5/2015 Annual review with no changes to clinical criteria. Deleted educational
statement and updated references.
5/2016 Annual review. Updated criteria to require only a diagnosis. Updated
references.
5/2017 Annual review with no changes to criteria.
5/2018 Annual review with no changes to clinical criteria. Updated references.
12/2018 Administrative change to add statement regarding use of automated
processes.
5/2019 Annual review with no changes to clinical criteria.
5/2020 Annual review with no changes to clinical criteria. Updated reference.
5/2021 Annual review with no changes to clinical criteria.
5/2022 Annual review with no change to clinical criteria. Updated reference.
5/2023 Annual review with no change to clinical criteria. Added state mandate
footnote. Updated reference.
5/2024 Annual review. Initial Authorization increased to 12 months.
5/2025 Annual review with no change to clinical criteria.
© 2025 UnitedHealthcare Services, Inc.
2